EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
Positive
AI Analysis
Summary
Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a German clinical-stage biotechnology company, for up to USD 5.0 billion. EQT Life Sciences is exiting its minority stake in Tubulis via this sale, following its Series B2 financing lead in March 2024.
Outcome Details
Definitive agreement entered for acquisition of Tubulis by Gilead Sciences
Importance:8/10
Sentiment:
0.60
M&AacquisitionGileadTubulisGermany-basedclinical-stageEQT Life Sciences
Related Companies
Read the original article
Published by PR Newswire Biotech on April 7, 2026 2:27 PM